Clinical Trial Update: Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma [NA]

View source ↗

Summary

A terminated clinical trial evaluated FDG-PET and MR perfusion imaging in patients with Neurofibromatosis Type 1 and plexiform neurofibromas, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• Fludeoxyglucose F-18 (Fludeoxyglucose F-18)

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: Neurofibromatosis Type 1, Precancerous Condition | NA | Status: TERMINATED | Results posted: 2014-04-04